Hormonal Contraception and the Eye: Does Contraceptive Choice Matter for Retinal Vascular Risk?

Background

Hormonal contraception is used by millions of women of reproductive age, but counseling usually focuses on pregnancy prevention and well-known cardiovascular and thrombotic risks. Ocular vascular complications are uncommon and may receive less attention during contraceptive counseling. Retinal vascular occlusion can cause significant visual impairment, making it important to understand whether different hormonal contraceptive methods carry different levels of ocular risk.

Methods

We conducted a focused review of recent epidemiologic and ophthalmologic literature examining hormonal contraception and retinal vascular outcomes. We compared findings according to contraceptive formulation, estrogen dose, and route of administration. We also reviewed evidence regarding retinal microvascular changes detected with optical coherence tomography angiography and considered clinical factors that may modify vascular risk.

Results

Recent population-level evidence suggests an association between hormonal contraception and retinal vein occlusion, although the absolute risk remains low. A nationwide cohort of more than 2.2 million women aged 15–49 years found a 40% higher rate of retinal vein occlusion among current hormonal contraceptive users compared with non-users. The association was more evident among users of combined oral contraceptives containing 30–40 μg of estrogen, while no increased rate was observed with 20 μg combined oral contraceptives or hormonal intrauterine devices. No significant increase was found for retinal artery occlusion. Separate retinal imaging research has found mostly minimal differences in retinal microvascular measurements among hormonal contraceptive users, suggesting that measurable retinal changes may be subtle.

Discussion & Conclusion

Ocular vascular complications associated with hormonal contraception appear to be uncommon, but available evidence suggests that contraceptive formulation may influence retinal vascular risk. These findings do not suggest that hormonal contraception should generally be avoided; rather, they support individualized counseling for women with additional vascular risk factors. A history of hypertension, smoking, migraine, diabetes, thrombophilia, or previous thrombotic disease may be particularly relevant when selecting a contraceptive method. Greater collaboration between obstetrics and gynecology and ophthalmology could improve recognition of uncommon ocular complications and help patients make informed contraceptive decisions. Further longitudinal research is needed to clarify which patients are most susceptible and whether retinal imaging has a role in future risk assessment.